MetLife Investment Management LLC Raises Position in Phreesia, Inc. (NYSE:PHR)

MetLife Investment Management LLC lifted its stake in shares of Phreesia, Inc. (NYSE:PHR) by 10.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,860 shares of the company’s stock after buying an additional 3,079 shares during the quarter. MetLife Investment Management LLC owned 0.06% of Phreesia worth $852,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PHR. Invesco Ltd. lifted its position in shares of Phreesia by 0.9% during the fourth quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock worth $1,013,000 after purchasing an additional 357 shares in the last quarter. NewEdge Advisors LLC increased its stake in Phreesia by 12.1% during the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock worth $107,000 after buying an additional 459 shares during the period. R Squared Ltd purchased a new position in Phreesia in the 4th quarter valued at about $30,000. BankPlus Trust Department acquired a new stake in shares of Phreesia during the fourth quarter valued at about $34,000. Finally, Swiss National Bank increased its position in shares of Phreesia by 1.3% during the fourth quarter. Swiss National Bank now owns 107,900 shares of the company’s stock worth $2,715,000 after acquiring an additional 1,400 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PHR has been the subject of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Citigroup upped their price target on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. KeyCorp decreased their price objective on shares of Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, April 16th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Canaccord Genuity Group lifted their price target on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.33.

Phreesia Price Performance

Shares of PHR opened at $25.67 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The company has a market cap of $1.51 billion, a P/E ratio of -17.46 and a beta of 0.74. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The stock has a fifty day moving average price of $25.22 and a 200 day moving average price of $24.54.

Insider Transactions at Phreesia

In other Phreesia news, SVP David Linetsky sold 4,499 shares of the company’s stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $23.73, for a total value of $106,761.27. Following the completion of the transaction, the senior vice president now owns 217,239 shares in the company, valued at approximately $5,155,081.47. This represents a 2.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Evan Roberts sold 16,005 shares of Phreesia stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $30.00, for a total value of $480,150.00. Following the sale, the chief operating officer now directly owns 748,302 shares in the company, valued at approximately $22,449,060. This trade represents a 2.09 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 112,660 shares of company stock worth $3,124,263. Insiders own 5.80% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.